GlassScriptPhysician profile
Shital Parikh
NPI 1538245907
$2,481.81
in general payments reported to CMS, 2019-2025
13 companies · $30.48 in 2025
The $30.48 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $116 · 2021: $260 · 2022: $669 · 2023: $534 · 2024: $669 · 2025: $30.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $756.29 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $425.22 | 2019-2022 | |
| Medtronic, INC. | $324.62 | 2022-2023 | Corevalve Evolut R |
| W. L. Gore & Associates, INC. | $305.85 | 2022-2024 | Gore Cardioform Septal Occluder |
| Impulse Dynamics (USA) INC. | $171.17 | 2024 | Optimizer |
| Abbott Laboratories | $167.50 | 2024 | Mitraclip |
| Genzyme Corporation | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $113.85 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $30.48 | 2025 | Tryvio |
| Astrazeneca Pharmaceuticals LP | $18.73 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.65 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.70 | 2022 | |
| Pfizer INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shital Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.